Get the Stockscreener App
1.45
2.84%
0.04
After Hours:
1.47
0.02
+1.38%
Medicinova Inc stock is traded at $1.45, with a volume of 48,279.
It is up +2.84% in the last 24 hours and up +2.84% over the past month.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
See More
Previous Close:
$1.41
Open:
$1.44
24h Volume:
48,279
Relative Volume:
0.96
Market Cap:
$71.37M
Revenue:
$409.70K
Net Income/Loss:
$-12.00M
P/E Ratio:
-5.9305
EPS:
-0.2445
Net Cash Flow:
$-9.81M
1W Performance:
+5.84%
1M Performance:
+2.84%
6M Performance:
+3.57%
1Y Performance:
-2.03%
1-Day Range:
$1.44
$1.485
1-Week Range:
$1.37
$1.485
52-Week Range:
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.45 | 69.40M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | H.C. Wainwright | Buy |
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest - MarketBeat
MediciNova (NASDAQ: MNOV) proxy targets 247M authorized shares, board elections - Stock Titan
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Weekly Voice
New Peer‑Reviewed Study Reveals Actionable - GlobeNewswire
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - MSN
Researchers found a brain metastasis weakness — MediciNova plans clinical work - Stock Titan
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
MediciNova (NASDAQ: MNOV) to vote on 147M share increase, director slate - Stock Titan
Valuation Metrics Overview | Medicinova posts narrower than expected loss, 48.4% EPS beatMarket Buzz Alerts - Newser
MediciNova (MNOV) asks shareholders to approve 147M share increase ahead of June meeting - Stock Titan
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What is the bear case for Medicinova (MNOV) Stock | Price at $1.48, Down 1.01%Continuation Pattern - Newser
Gainers Report: What is the next catalyst for MediciNova IncMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Nasdaq Moves: Whats the MACD signal for MediciNova Inc2026 Spike Watch & Breakout Confirmation Trade Signals - baoquankhu1.vn
Fed Meeting: What is the next catalyst for MediciNova IncRecession Risk & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Investor Mood: What analysts say about MediciNova Inc stockSell Signal & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc expand its profit marginsQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
BYSI PE Ratio & Valuation, Is BYSI Overvalued - Intellectia AI
Sentiment Watch: How sensitive is MediciNova Inc to inflationWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Will Medicinova (MNOV) Stock Hit Record Highs | Price at $1.44, Up 1.41%High Reward Trade - Newser
Buy Signal: What is the next catalyst for MediciNova IncEarnings Risk Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Winners Losers: Can MediciNova Inc beat the S P 500Forecast Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Medicinova Inc (NASDAQ:MNOV) Reiterates Buy Rating - FXDailyReport.Com
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova Inc stock draws attention amid biotech pipeline momentum and analyst upside calls - AD HOC NEWS
MediciNova (NASDAQ:MNOV) Upgraded at Zacks Research - Defense World
MediciNova (NASDAQ:MNOV) Raised to "Hold" at Zacks Research - MarketBeat
What is HC Wainwright’s Estimate for MediciNova Q1 Earnings? - Defense World
Q1 Earnings Estimate for MediciNova Issued By HC Wainwright - MarketBeat
HC Wainwright & Co. initiates coverage of MediciNova (MNOV) with buy recommendation - MSN
Stock Analysis: Can MediciNova Inc continue delivering strong returnsQuarterly Risk Review & Verified Swing Trading Watchlist - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Now Covered by HC Wainwright - MarketBeat
MediciNova to Participate at the 38th Annual ROTH Conference - Bitget
This Cohu Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
MediciNova Inc Stock (ISIN: US58468P2038) Surges on Clinical Trial Momentum—Analysts See 469% Upsi - AD HOC NEWS
MediciNova, Inc. 2025 Annual Report: Advancing MN-166 and MN-001 Therapies for Neurological and Metabolic Diseases - Minichart
Medicinova 2025 10-K: Revenue $0.41M, EPS $(0.24) - TradingView
MediciNova (NASDAQ: MNOV) highlights MN-166 and MN-001 progress in annual report - Stock Titan
Quarterly Recap: What is the next catalyst for MediciNova IncChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Trend Review: Is MediciNova Inc a stock for growth or value investorsWeekly Trading Summary & AI Forecasted Stock Moves - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can MediciNova Inc continue delivering strong returnsMarket Activity Recap & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Analyst Calls: Can AACG be recession proofJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MediciNova (MNOV) Price Target Increased by 11.11% to 10.20 - Nasdaq
Breakout Watch: What analysts say about MediciNova Inc stockGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Moves: Can MediciNova Inc continue delivering strong returns2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):